secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2025-07-21T23:59:59+00:00
Accession:  0001193125-25-161516
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places clinical hold on Sarepta's LGMD gene therapy trials; revokes AAVrh74 platform designation
--------------------------------------------------------------------------------

- FDA placed clinical hold on LGMD trials for SRP-9003, SRP-9004, SRP-6004, and SRP-9005.
- Sarepta had paused most LGMD programs on July 16, 2025; SRP-9003 was excepted.
- FDA revoked AAVrh74 platform technology designation previously granted on June 2, 2025.
- Sarepta plans to discuss accelerated approval pathway for SRP-9003 after clinical hold lifted.
- Enrollment and dosing in Phase 3 trial SRP-9003-301 was completed in December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312525161516/0001193125-25-161516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312525161516/d882671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-161516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer